Skip to main content
Fig. 3 | Biomaterials Research

Fig. 3

From: Nanoarchitectured conjugates targeting angiogenesis: investigating heparin-taurocholate acid conjugates (LHT7) as an advanced anti-angiogenic therapy for brain tumor treatment

Fig. 3

Anti-proliferation effect of LHT7 on HUVEC cells. a Cell viability of HUVECs in the presence or absence of VEGF (10 μg/mL) or EGF (10 μg/mL). Data are expressed as mean ± SEM (n = 5). b Cell viability of U87MG with LHT7 treatment in the concentration range of 0–100 μg/m. Data are expressed as mean ± SEM (n = 5). c Cell viability of HUVECs in the presence of growth factors (VEGF or EGF) and LHT in the concentration range of 0–100 μg/mL. Data are expressed as mean ± SEM (n = 5

Back to article page